美迪西股价跌5.15%，前海开源基金旗下1只基金重仓，持有1万股浮亏损失2.89万元

Company Overview - Shanghai Medicilon Inc. is located at 585 Chuan Da Road, Chuansha New Town, Pudong New District, Shanghai, and was established on February 2, 2004. The company went public on November 5, 2019. Its main business involves providing comprehensive new drug research and development services for pharmaceutical companies and other new drug research institutions [1] - The revenue composition of the company is as follows: 50.34% from preclinical research, 49.64% from drug discovery and pharmaceutical research, and 0.01% from other supplementary services [1] Stock Performance - On December 2, Medicilon's stock fell by 5.15%, closing at 53.26 CNY per share, with a trading volume of 167 million CNY and a turnover rate of 2.30%. The total market capitalization is 7.156 billion CNY [1] Fund Holdings - The Qianhai Kaiyuan China Growth Mixed Fund (000788) holds 10,000 shares of Medicilon, representing 1.23% of the fund's net value, making it the tenth largest holding. The estimated floating loss today is approximately 28,900 CNY [2] - The Qianhai Kaiyuan China Growth Mixed Fund was established on September 29, 2014, with a latest scale of 56.4282 million CNY. Year-to-date returns are 18.68%, ranking 4342 out of 8122 in its category; one-year returns are 19.35%, ranking 4095 out of 8056; and since inception, the fund has returned 55.63% [2]